Both in Pharmaceuticals
Vertex Pharmaceuticals vs Bristol-Myers Squibb
Over the past year VRTX returned +33.2% and BMY returned +42.4%; their daily moves had a correlation of 0.44.
VRTX +33.2% BMY +42.4%Growth of $1, one year, split-adjusted
| Metric | VRTX | BMY |
|---|---|---|
| Price | $526.73 | $62.86 |
| Market cap | $133.51B | $128.41B |
| Today | −0.18% | −1.60% |
| 1 month | −2.8% | −5.6% |
| 6 months | +18.9% | +5.2% |
| Year to date | +16.2% | +16.5% |
| 1 year | +36.6% | +42.5% |
| Revenue growth (YoY) | +12.5% | +5.7% |
| Gross margin | 85.3% | 71.3% |
| Net margin | 33.0% | 25.6% |
| P/E (TTM) | 30.3× | 13.8× |
| Price / sales | 10.6× | 2.6× |
| Net cash | $7.85B | -$32.05B |
| Dividend yield | — | 4.01% |
| Volatility (60d) | 26.6% | 25.2% |
| Short % of float | 1.9% | 2.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).